title: Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.
abstract: The consensus of current international guidelines for the treatment of HIV infection is that data on therapeutic drug monitoring (TDM) of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (Pls) provide a framework for the implementation of TDM in certain defined scenarios in clinical practice. However, the utility of TDM is considered to be on an individual basis until more data are obtained from large clinical trials showing the benefit of TDM. In April 2004, a panel of experts met for the second time in Rome, Italy. This was following the inaugural meeting in Perugia, Italy, in October 2000, which resulted in the manuscript published in AIDS 2002, 16(Suppl 1):S5-S37. The objectives of this second meeting were to review and update the numerous questions surrounding TDM of antiretroviral drugs and discuss the clinical utility, current concerns and future prospects of drug concentration monitoring in the care of HIV-1-infected individuals. A major focus of the meeting was to discuss and critically analyse recent and precedent clinical drug-drug interaction data to provide a clear framework of the pharmacological basis of how one drug may impact the disposition of another. This report, which has been updated to include material published or presented at international conferences up to the end of December 2004, reviews recent pivotal pharmacokinetic interaction data and provides advice to clinical care providers on how some drug-drug interactions may be prevented, avoided or managed, and, when data are available, on what dose adjustments and interventions should be performed.
authors.affiliation: Chelsea and Westminster Hospital, London, UK. marta.boffito@chelwest.nhs.uk
authors.forename: Marta
authors.initials: M
authors.lastname: Boffito
authors.forename: Edward
authors.initials: E
authors.lastname: Acosta
authors.forename: David
authors.initials: D
authors.lastname: Burger
authors.forename: Courtney V
authors.initials: CV
authors.lastname: Fletcher
authors.forename: Charles
authors.initials: C
authors.lastname: Flexner
authors.forename: Rodolphe
authors.initials: R
authors.lastname: Garaffo
authors.forename: Giorgio
authors.initials: G
authors.lastname: Gatti
authors.forename: Michael
authors.initials: M
authors.lastname: Kurowski
authors.forename: Carlo Federico
authors.initials: CF
authors.lastname: Perno
authors.forename: Gilles
authors.initials: G
authors.lastname: Peytavin
authors.forename: Mario
authors.initials: M
authors.lastname: Regazzi
authors.forename: David
authors.initials: D
authors.lastname: Back
mesh_terms: D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000494:pharmacology*; D004347:Drug Interactions; D016903:Drug Monitoring / Q000639:trends*; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D017410:Practice Guidelines as Topic; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology*
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors